Novo Nordisk introduces Victoza in China for type 2 diabetes
Victoza is a once-daily human Glucagon-Like Peptide-1 (GLP-1) analogue which works by stimulating the beta cells to release insulin only when blood sugar levels are high. The injection
HAYA Therapeutics has secured fast track designation from the US Food and Drug Administration (FDA) for its investigational therapy, HTX-001, to treat symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM).